A detailed history of Royal Bank Of Canada transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 2,842 shares of FHTX stock, worth $21,371. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,842
Previous 9,376 69.69%
Holding current value
$21,371
Previous $53,000 50.94%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$4.8 - $9.99 $31,363 - $65,274
-6,534 Reduced 69.69%
2,842 $26,000
Q2 2024

Aug 14, 2024

BUY
$5.05 - $8.0 $4,686 - $7,424
928 Added 10.98%
9,376 $53,000
Q1 2024

Nov 05, 2024

SELL
$2.82 - $7.94 $2,616 - $7,368
-928 Reduced 9.9%
8,448 $56,000
Q1 2024

May 15, 2024

BUY
$2.82 - $7.94 $5,490 - $15,459
1,947 Added 29.95%
8,448 $56,000
Q4 2023

Feb 14, 2024

BUY
$2.94 - $6.76 $902 - $2,075
307 Added 4.96%
6,501 $41,000
Q3 2023

Nov 14, 2023

SELL
$5.0 - $9.87 $6,360 - $12,554
-1,272 Reduced 17.04%
6,194 $30,000
Q2 2023

Aug 14, 2023

SELL
$5.37 - $8.84 $182 - $300
-34 Reduced 0.45%
7,466 $52,000
Q1 2023

May 15, 2023

BUY
$4.66 - $8.99 $5,130 - $9,897
1,101 Added 17.21%
7,500 $46,000
Q4 2022

Feb 14, 2023

BUY
$5.44 - $9.46 $16,069 - $27,944
2,954 Added 85.75%
6,399 $40,000
Q3 2022

Nov 14, 2022

BUY
$7.52 - $18.01 $992 - $2,377
132 Added 3.98%
3,445 $29,000
Q2 2022

Aug 15, 2022

SELL
$8.48 - $16.84 $9,234 - $18,338
-1,089 Reduced 24.74%
3,313 $46,000
Q1 2022

May 16, 2022

SELL
$8.87 - $22.1 $24,090 - $60,023
-2,716 Reduced 38.16%
4,402 $67,000
Q4 2021

Feb 14, 2022

BUY
$10.79 - $22.87 $16,951 - $35,928
1,571 Added 28.32%
7,118 $162,000
Q3 2021

Nov 15, 2021

BUY
$8.33 - $15.02 $24,648 - $44,444
2,959 Added 114.34%
5,547 $78,000
Q2 2021

Aug 16, 2021

BUY
$9.32 - $13.26 $24,120 - $34,316
2,588 New
2,588 $27,000

Others Institutions Holding FHTX

About Foghorn Therapeutics Inc.


  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $313M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.